REDESIGNING ANTIBODY DRUGS FROM THE GROUND UP
Xencor is expanding the therapeutic boundaries of monoclonal antibody drugs. Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat cancer and autoimmune disorders. 17 programs are in clinical testing, and many more are in preclinical development.
XmAb Fc domains can be substituted into nearly any antibody, creating the basis for numerous partnerships.
Diversified Antibody Drug Pipeline
Our unique portfolio of XmAb-engineered Fc domains enable highly selective immune-modulators and targeted cancer therapies.
Unleashing Bispecific Antibodies
Our technology can simultaneously address multiple disease targets while improving half-life, stability and ease of manufacturing.